AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive: CML-HMGB1 was modified via oxidation and more pronouncedly activated the receptor for AGE and downstream AKT and NF-κB compared to naïve HMGB1 and oxidized HMGB1.